ARMP - AMEX
Armata Pharmaceuticals, Inc.
$7.69
-2.9%Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
At a Glance
Live Snapshotarmp
Other Current Liabilities
Last Annual Value
3.46M
3-Year CAGR
%
5-Year CAGR
12%
10-Year CAGR
23%
Armata Pharmaceuticals, Inc. Competitors Analysis of Other Current Liabilities
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Armata Pharmaceuticals, Inc. AMEX:ARMP | 3.46M | 38.9% | N/A | 15.4% | |
 SELLAS Life Sciences Group, Inc. NASDAQ:SLS | 3.52M | 31.9% | 16.4% | 5.8% | |
 Nuvectis Pharma, Inc. NASDAQ:NVCT | 7.02M | 22.7% | 118.2% | N/A | |
 Neonc Technologies Holdings, Inc. NASDAQ:NTHI | 255.10K | -38.4% | -11.2% | N/A | |
 Codexis, Inc. NASDAQ:CDXS | 13.81M | 7.1% | 4.4% | 30.8% | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 13.31M | 12.4% | 19.4% | N/A | |
 Insight Molecular Diagnostics Inc. NASDAQ:IMDX | 7.72M | 24.4% | 2.9% | 66.9% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 25.43M | 29.4% | 4.1% | 22.3% | |
 OmniAb, Inc. NASDAQ:OABI | 7.33M | -2.0% | 8.3% | N/A |
Armata Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your ARMP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.